
Rx Rundown: BioNTech, Merck, RayzeBio and more
Deals: BioNTech agreed to acquire CureVac for about $1.25 billion in an all-stock deal. RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 …